These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 29043514)

  • 1. Efficacy of a triplet and doublet-based chemotherapy as first-line therapy in patients with HER2-negative metastatic gastric cancer: a retrospective analysis from the clinical practice.
    Laterza MM; Pompella L; Petrillo A; Tirino G; Pappalardo A; Orditura M; Troiani T; Ciardiello F; Di Martino N; De Vita F
    Med Oncol; 2017 Oct; 34(11):186. PubMed ID: 29043514
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is there a preferred platinum and fluoropyrimidine regimen for advanced HER2-negative esophagogastric adenocarcinoma? Insights from 1293 patients in AGAMENON-SEOM registry.
    Arias-Martinez A; Martínez de Castro E; Gallego J; Arrazubi V; Custodio A; Fernández Montes A; Diez M; Hernandez R; Limón ML; Cano JM; Vidal-Tocino R; Macias I; Visa L; Martin Richard M; Sauri T; Hierro C; Gil M; Cerda P; Martínez Moreno E; Martínez Lago N; Mérida-García AJ; Gómez González L; García Navalón FJ; Ruiz Martín M; Marín G; López-López F; Ruperez Blanco AB; Fernández AF; Jimenez-Fonseca P; Carmona-Bayonas A; Alvarez-Manceñido F
    Clin Transl Oncol; 2024 Jul; 26(7):1674-1686. PubMed ID: 38361134
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [FOLFOX regimen in the patients with locally advanced or metastatic gastric cancer].
    Yan D; Dai H
    Zhonghua Zhong Liu Za Zhi; 2009 Mar; 31(3):217-9. PubMed ID: 19615264
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modified docetaxel and cisplatin in combination with capecitabine (DCX) as a first-line treatment in HER2-negative advanced gastric cancer.
    Bilici A; Selcukbiricik F; Demir N; Oven Ustaalioglu BB; Dikilitas M; Yildiz O
    Asian Pac J Cancer Prev; 2014; 15(20):8661-6. PubMed ID: 25374186
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of efficacy and safety of first-line palliative chemotherapy with EOX and mDCF regimens in patients with locally advanced inoperable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma: a randomized phase 3 trial.
    Ochenduszko S; Puskulluoglu M; Konopka K; Fijorek K; Urbanczyk K; Budzynski A; Matlok M; Lazar A; Sinczak-Kuta A; Pedziwiatr M; Krzemieniecki K
    Med Oncol; 2015 Oct; 32(10):242. PubMed ID: 26354521
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FOLFOX (oxaliplatin and 5 fluorouracil/leucovorin) in patients with untreated metastatic gastric adenocarcinoma Phase II study.
    Mohammad HA; Magdy FM; Mahmoud OM
    Indian J Cancer; 2011; 48(4):460-5. PubMed ID: 22293261
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modified FOLFOX-6 therapy for heavily pretreated advanced gastric cancer refractory to fluorouracil, irinotecan, cisplatin and taxanes: a retrospective study.
    Tsuji K; Yasui H; Onozawa Y; Boku N; Doyama H; Fukutomi A; Yamazaki K; Machida N; Todaka A; Taniguchi H; Tsushima T; Yokota T
    Jpn J Clin Oncol; 2012 Aug; 42(8):686-90. PubMed ID: 22693245
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospective, randomized, multicenter, phase III study of fluorouracil, leucovorin, and irinotecan versus epirubicin, cisplatin, and capecitabine in advanced gastric adenocarcinoma: a French intergroup (Fédération Francophone de Cancérologie Digestive, Fédération Nationale des Centres de Lutte Contre le Cancer, and Groupe Coopérateur Multidisciplinaire en Oncologie) study.
    Guimbaud R; Louvet C; Ries P; Ychou M; Maillard E; André T; Gornet JM; Aparicio T; Nguyen S; Azzedine A; Etienne PL; Boucher E; Rebischung C; Hammel P; Rougier P; Bedenne L; Bouché O
    J Clin Oncol; 2014 Nov; 32(31):3520-6. PubMed ID: 25287828
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized prospective phase II study to compare the combination chemotherapy regimen epirubicin, cisplatin, and 5-fluorouracil with epirubicin, cisplatin, and capecitabine in patients with advanced or metastatic gastric cancer.
    Ocvirk J; Reberšek M; Skof E; Hlebanja Z; Boc M
    Am J Clin Oncol; 2012 Jun; 35(3):237-41. PubMed ID: 21399488
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Efficacy and Safety of FOLFIRI after Failure of FOLFOX-4 in Advanced Gastric Cancer].
    Kwon HJ; Park MI; Park SJ; Moon W; Kim SE; Lee HW; Choi YJ; Kim JH
    Korean J Gastroenterol; 2015 Jul; 66(1):10-6. PubMed ID: 26194124
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of trastuzumab in combination with oxaliplatin and fluorouracil-based chemotherapy for patients with HER2-positive metastatic gastric and gastro-oesophageal junction adenocarcinoma patients: a retrospective study.
    Soularue É; Cohen R; Tournigand C; Zaanan A; Louvet C; Bachet JB; Hentic O; Samalin E; Chibaudel B; de Gramont A; André T;
    Bull Cancer; 2015 Apr; 102(4):324-31. PubMed ID: 25744576
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ipilimumab or FOLFOX with Nivolumab and Trastuzumab in previously untreated HER2-positive locally advanced or metastatic EsophagoGastric Adenocarcinoma - the randomized phase 2 INTEGA trial (AIO STO 0217).
    Tintelnot J; Goekkurt E; Binder M; Thuss-Patience P; Lorenzen S; Knorrenschild JR; Kretzschmar A; Ettrich T; Lindig U; Jacobasch L; Pink D; Al-Batran SE; Hinke A; Hegewisch-Becker S; Nilsson S; Bokemeyer C; Stein A
    BMC Cancer; 2020 Jun; 20(1):503. PubMed ID: 32487035
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study.
    Iveson T; Donehower RC; Davidenko I; Tjulandin S; Deptala A; Harrison M; Nirni S; Lakshmaiah K; Thomas A; Jiang Y; Zhu M; Tang R; Anderson A; Dubey S; Oliner KS; Loh E
    Lancet Oncol; 2014 Aug; 15(9):1007-18. PubMed ID: 24965569
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of intraperitoneal and intravenous chemotherapy for advanced gastric cancer with peritoneal metastasis.
    Chen Y; Wang XJ; Lin RB; Chen L; Lin G; Guo ZQ
    Tumori; 2014; 100(5):e180-8. PubMed ID: 25343556
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Docetaxel-oxaliplatin-capecitabine/5-fluorouracil (DOX/F) followed by docetaxel versus oxaliplatin-capecitabine/5-fluorouracil (CAPOX/FOLFOX) in HER2-negative advanced gastric cancers.
    Ramaswamy A; Bhargava P; Dubashi B; Gupta A; Kapoor A; Srinivas S; Shetty O; Jadhav P; Desai V; Noronha V; Joshi A; Menon N; Patil VM; Mishra BK; Sansar B; Singh A; Patel S; Singh SN; Dhal I; Vinayak KR; Pal V; Mandavkar S; Kannan S; Chaugule D; Patil R; Parulekar M; Nashikkar C; Ankathi SK; Kaushal RK; Shah A; Ganesan P; Kayal S; Ananthakrishnan R; Syed N; Samaddar D; Kapu V; Shah A; Kaaviya D; Suganiya R; Srinivasan ND; Prabhash K; Ostwal V
    JNCI Cancer Spectr; 2024 Jul; 8(4):. PubMed ID: 39067037
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase III randomized trial comparing 5-fluorouracil and oxaliplatin with or without docetaxel in first-line advanced gastric cancer chemotherapy (GASTFOX study).
    Zaanan A; Samalin E; Aparicio T; Bouche O; Laurent-Puig P; Manfredi S; Michel P; Monterymard C; Moreau M; Rougier P; Tougeron D; Taieb J; Louvet C
    Dig Liver Dis; 2018 Apr; 50(4):408-410. PubMed ID: 29409778
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of advanced oesophagogastric cancer with FOLFOX-4 regimen followed by leucovorin/bolus and continuous infusion 5-FU as maintenance chemotherapy in patients aged ≥ 75 years with impaired performance status.
    Petrioli R; Francini E; Roviello F; Marrelli D; Miano ST; Fiaschi AI; Laera L; Bellini MA; Roviello G
    J Geriatr Oncol; 2015 Sep; 6(5):380-6. PubMed ID: 26228711
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A pilot study of oxaliplatin, fluorouracil and folinic acid (FOLFOX-6) as first-line chemotherapy in advanced or recurrent gastric cancer.
    Luo HY; Xu RH; Zhang L; Li YH; Shi YX; Lin TY; Han B; Wang F; Qiu MZ; He YJ; Guan ZZ
    Chemotherapy; 2008; 54(3):228-35. PubMed ID: 18560231
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical significance of bolus 5-fluorouracil for recurrent or metastatic colorectal cancer treated with FOLFOX+ BevacizumabTherapy].
    Yoshida Y; Hasegawa J; Nishimura J; Hirota M; Kim Y; Nezu R
    Gan To Kagaku Ryoho; 2011 Aug; 38(8):1293-6. PubMed ID: 21829066
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modified FOLFOX-4 as first-line and salvage treatment in advanced gastric cancer.
    Baek YH; Choi SR; Jang JS; Roh MH; Lee JH; Won JJ; Lee CM
    Hepatogastroenterology; 2011; 58(105):251-6. PubMed ID: 21510324
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.